Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: tbd
Format: PDF & Online Database
Product Line: Target Pipeline Review
Product Code: LMTP0151
Release Date: On the same day of purchase
Loading...

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Target: Folate Receptor alpha (FRα)

Product Category: Antibody; Cell; Radiopharmaceutical; Small Molecule; Vaccine

This product provides basic information on approved drugs and drug candidates in research and development targeting folate receptor alpha (FRα).

This product consists of:

  • Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage.
  • Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
  • One-month online access to La Merie Publishing’s database for FRα-targeted drugs and drug candidates (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is clinically validated target with commercial potential.

Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01

Error: Contact form not found.